1,861
Participants
Start Date
October 7, 2017
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Standard inactivated influenza vaccine (NH formulation)
0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
High-dose inactivated influenza vaccine (NH formulation)
0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)
0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
The University of Hong Kong, Hong Kong
Centers for Disease Control and Prevention
FED
The University of Hong Kong
OTHER